CME

Podcast

Oncology PER® Spectives™: Addressing Pivotal Updates in AML – Expert Perspectives on Individualizing Management for Special Populations

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

This PER® Spectives™ podcast episode, leading experts in acute myeloid leukemia (AML) discuss personalized management strategies for therapy-related AML and AML with IDH1 mutations, NPM1 mutations, and KMT2A rearrangements. Through engaging case studies and expert commentary, the panel delves into molecular testing, current and emerging therapies, and the role of innovative treatments like menin inhibitors. Designed for healthcare professionals, this episode provides actionable insights to guide treatment decisions and improve outcomes for special patient populations. Tune in to stay at the forefront of AML care.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Rigel Pharmaceuticals.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Instructions on How to Receive Credit

  • Listen to this podcast in its entirety.
  • Go to gotoper.com/credit and enter code: 3283
  • Answer the evaluation questions.
  • Request credit using the drop-down menu.
  • You may immediately download your certificate.

Today’s faculty are:

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

DisclosuresGrant/Research Support: Astellas Pharma, Bristol Myers Squibb, Eisai; Consultant: Astellas Pharma, AstraZeneca, Daiichi-Sankyo, Johnson & Johnson, Kura Oncology, Servier, Syndax Pharmaceuticals.

Marina Kremyanskaya, MD, PhD
Associate Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, NY

DisclosuresConsultant: AbbVie, Agios, Disc Medicine, Incyte, Kura Oncology, MorphoSys, Protagonist Therapeutics, Silence Therapeutics.

Hannah Levavi, MD
Assistant Professor of Medicine, Hematology and Medical Oncology
Icahn School of Medicine at Mount Sinai
Adult Leukemia Program
The Tisch Cancer Institute
New York, NY

Disclosures: Consultant: Sobi.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

January 16, 2025

Expiration Date

January 16, 2026